Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 20/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL565967 | 0.83 | GRM2 (0.60) | GRM2 | |
| SCHEMBL565694 | 0.83 | GRM2 (0.60) | GRM2 | |
| SCHEMBL15254848 | 0.80 | GRM2 (0.52) | GRM2 | |
| SCHEMBL921376 | 0.80 | GRM2 (0.41) | GRM2 | |
| SCHEMBL15254870 | 0.80 | GRM2 (0.49) | GRM2 | |
| SCHEMBL19139446 | 0.78 | GRM2 (0.77) | GRM2 | |
| SCHEMBL921507 | 0.76 | GRM2 (0.39) | GRM2 | |
| SCHEMBL921508 | 0.76 | GRM2 (0.39) | GRM2 | |
| SCHEMBL922105 | 0.75 | GRM2 (1.00) | GRM2 | |
| SCHEMBL921638 | 0.75 | GRM2 (0.38) | GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2220083-B1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2825538-B1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | BRISTOL MYERS SQUIBB CO (US) | 2016-06-01 | — | — | EP | disclosed |
| EP-2825538-A1 | POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 | Bristol-Myers Squibb Company (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785486-B2 | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8765767-B2 | Positive allosteric modulators of mGluR2 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-01 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | BRISTOL-MYERS SQUIBB COMPANY | 2013-09-19 | — | — | US | disclosed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| EP-2373649-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Ortho-McNeil-Janssen Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009441-A1 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM1, GRIA2 | GRM2 1/4885 |
| US-20130245042-A1 | Positive Allosteric Modulators of MGLUR2 | GRM2, GRM1, GRIN2C | GRM2 1/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | GRM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.